Read by QxMD icon Read

Journal of Drugs in Dermatology: JDD

Stanislav N Tolkachjov, Mark D P Davis, James A Yiannias
Crusted scabies (CS) is a highly infectious hyperinfestation variant of scabies with up to millions of Sarcoptes scabiei mites present on the skin surface. Diagnostic clues include intense itching and thick crusting especially on the face, groin, and buttocks, although variable presentations may mimic other dermatoses. CS has been associated with immunosuppression including the human immunodeficiency virus (HIV) and lymphoreticular malignancies.1-3 A long latency period from symptom onset to diagnosis and appropriate treatment is often reported...
October 1, 2018: Journal of Drugs in Dermatology: JDD
Erin Gilbert, Jia Zhu, Tao Peng, Nicole L Ward
Herpes Labialis results from reactivation of latent herpes simplex virus (HSV-1 or HSV-2) harbored in the trigeminal ganglion during times of psychological stress, cutaneous injury or photo exposure. Following reactivation, the virus is anterogradely transported through axonal termini to the skin where the virus is released and replicates causing a clinical outbreak. Botulinum neurotoxin A (BoNTA) is known to inhibit presynaptic neuropeptide and neurotransmitter release. Whether it has the capacity to interfere with viral shedding and delivery into the skin remains unclear...
October 1, 2018: Journal of Drugs in Dermatology: JDD
Adrian Cuellar-Barboza, Jesus Alberto Cardenas-De La Garza, Cesar Daniel Villarreal-Villarreal, Jorge Ocampo-Candiani, Minerva Gomez-Flores, Oliverio Welsh, Maira E Herz-Ruelas
Bullous morphea is rare clinical variant of localized scleroderma characterized by the formation of bullae on sclerotic morphea plaques. Severe disease may be highly disabling and greatly impair quality of life. Current treatment strategies are based on anecdotal reports of clinical experience and include topical corticosteroids, methotrexate and phototherapy. Herein, we describe the case of a 56-year-old woman with progressive bullous sclerotic lesions who was successfully treated with mycophenolate mofetil after treatment failure with psoralen plus ultraviolet A therapy, ultraviolet A1 phototherapy, and methotrexate...
October 1, 2018: Journal of Drugs in Dermatology: JDD
Eduardo Anitua, Ander Pino, María Troya
In this study, the stability of a novel autologous topical serum (ATS) derived from plasma rich in growth factors technology (PRGF) has been evaluated. As skin ages, mechanical, protective and restorative properties decrease leading to multiple clinical conditions. In recent years, topical administration of growth factors has emerged as a promising therapeutic alternative to promote wound healing and skin regeneration. Determination of stability is a crucial step in the formulation process in order to develop an effective product...
October 1, 2018: Journal of Drugs in Dermatology: JDD
Laetitia Amar, Leon H Kircik
BACKGROUND: Acne vulgaris (acne) is the most common skin disease in patients who have darker skin with most frequent sequelae of post inflammatory hyperpigmentation (PIH). METHODS: Open label study in 20 patients (mean age 32 years) with Fitzpatrick Skin Type V or VI and with moderate facial acne treated with clindamycin phosphate 1.2%/benzoyl peroxide 3.75% gel (CL-BP 3.75%) once-daily for 16 weeks. Assessments included improvement in Investigator Global Assessment (IGA) of acne severity, PIH severity and distribution, and lesion count reduction...
October 1, 2018: Journal of Drugs in Dermatology: JDD
Stephen K Tyring, Theodore Rosen, Brian Berman, Nathan Stasko, Todd Durham, Tomoko Maeda-Chubachi
BACKGROUND: Nitric oxide (NO), a free radical gas, is endogenously produced in human cells. In high concentration, NO neutralizes many disease-causing microbes. The topical investigational drug SB206 releases NO and has the potential to treat skin diseases caused by viruses. Genital warts (condyloma acuminata) are primarily caused by human papillomavirus (HPV) types 6 and 11. Available treatments have low tolerability and efficacy rates and are inconvenient for the patient. Genital warts can recur if HPV is incompletely eradicated during treatment...
October 1, 2018: Journal of Drugs in Dermatology: JDD
Stacy R Smith, Shuai Xu, Esther Estes, Stuart D Shanler
OBJECTIVE: Seborrheic keratoses (SKs) may present in any non-glabrous skin, but data are limited on the response to treatment as based on the SK location. We aimed to understand the relationship between SK location and clearance with up to 2 treatments of 40% (w/w) hydrogen peroxide topical solution (HP40). METHODS: We conducted a sub-analysis of data pooled from two randomized, double-blind, vehicle (VEH)-controlled clinical trials, including 937 patients, each with 4 target SKs (N=3,748 SKs), with at least 1 on the face and 1 on the trunk or extremities...
October 1, 2018: Journal of Drugs in Dermatology: JDD
Stephen K Tyring, Leon H Kircik, David M Pariser, Eric Guenin, Varsha Bhatt, Radhakrishnan Pillai
BACKGROUND: Topical tretinoin has been extensively studied in clinical trials, and its essential role in the treatment of acne vulgaris (acne) established through evidence-based guidelines. OBJECTIVE: To evaluate efficacy, safety, and tolerability of a novel tretinoin 0.05% lotion in moderate-to-severe acne in patients aged 9 years and older. METHODS: A total of 1640 patients, 9-58 years of age were randomized to receive tretinoin 0.05% lotion or vehicle in two double-blind, placebo-controlled 12-week, 2-arm, parallel group studies evaluating safety and efficacy (inflammatory and noninflammatory lesion counts and acne severity using Evaluator Global Severity Scores [EGSS])...
October 1, 2018: Journal of Drugs in Dermatology: JDD
Jerry Bagel, Ahmed S Samad, Bradley S Stolshek, Girish A Aras, James B Chung, Gregory Kricorian, Leon H Kircik
INTRODUCTION: Response to etanercept therapy in patients who have failed apremilast therapy has not been well characterized. METHODS: In this multicenter, open-label, single-arm, phase 4, estimation study, subjects with moderate to severe plaque psoriasis received etanercept 50 mg SC twice weekly for 12 weeks, followed by etanercept 50 mg SC once weekly for an additional 12 weeks. Subjects had BSA greater than equal to 10%, PASI greater than equal to 10, and sPGA greater than equal to 3 at screening and baseline; and had failed apremilast-because of either failure to achieve or loss of adequate clinical response, or intolerability to apremilast in the opinion of the investigator...
October 1, 2018: Journal of Drugs in Dermatology: JDD
James Q Del Rosso, Julie Harper, Leon Kircik, Glynis Albon, Diane Berson, Adelaide Hebert, Doris Day
Atopic dermatitis (AD) is well-recognized as a very common chronic and relapsing pruritic skin disorder affecting both children and adults worldwide. The adverse effects on the quality of life of affected individuals and their families is well-established. The pathophysiology of AD is complex, leading to interindividual variations in clinical presentation and severity. The chronicity of AD, characterized by periods of exacerbation and remission, supports a strong need to develop measures that can effectively and safely prolong remissions between flares of the disease...
October 1, 2018: Journal of Drugs in Dermatology: JDD
Lawrence J Green, Francisco A Kerdel, Fran E Cook-Bolden, Jerry Bagel, Tina Lin, Gina Martin, Radhakrishnan Pillai, Robert Israel, Tage Ramakrishna
BACKGROUND: Topical corticosteroids (TCS) are the mainstay of psoriasis treatment; long-term safety concerns limiting consecutive use of potent TCS to 2-4 weeks. OBJECTIVE: Investigate safety and efficacy of halobetasol propionate 0.01% lotion in moderate-to-severe plaque psoriasis. METHODS: Two multicenter, randomized, double-blind, vehicle-controlled phase 3 studies (N=430). Subjects randomized (2:1) to halobetasol propionate 0.01% lotion or vehicle once-daily for 8 weeks, 4-week posttreatment follow-up...
October 1, 2018: Journal of Drugs in Dermatology: JDD
Ryan S Din, William G Tsiaras, David G Li, Arash Mostaghimi
INTRODUCTION: Pyoderma gangrenosum (PG) is a neutrophilic dermatosis commonly treated with steroid immunosuppression. The utility of dapsone as a non-immunosuppressive treatment for PG has been reported in case reports and series. We sought to evaluate the response and tolerability of concurrent systemic dapsone therapy for treating PG. METHODS: We reviewed PG patients treated with systemic dapsone at Massachusetts General Hospital and Brigham and Women's Hospital from 2000-2015...
October 1, 2018: Journal of Drugs in Dermatology: JDD
Adelaide A Hebert, Nuria Albareda, Theodore Rosen, Antonio Torrelo, Ramon Grimalt, Noah Rosenberg, Ilonka Zsolt, Xavier Masramon
Ozenoxacin is a novel topical antibacterial agent with potent bactericidal activity against Gram-positive bacteria that has been developed as a 1% cream for treatment of impetigo. This article presents pooled results of pivotal clinical trials of ozenoxacin with the objective of evaluating the efficacy, safety, and tolerability of ozenoxacin 1% cream after twice-daily topical treatment for 5 days in patients with impetigo. A pooled analysis was performed of individual patient data from two multicenter, randomized, double-blind, vehicle-controlled phase 3 registration studies conducted in patients with impetigo...
October 1, 2018: Journal of Drugs in Dermatology: JDD
Jyotsna Chandra, Mauricio Retuerto, Sophie Seité, Richard Martin, Michaela Kus, Mahmoud A Ghannoum, Elma Baron, Pranab K Mukherjee
INTRODUCTION: Atopic dermatitis (AD) is associated with changes in skin bacterial microbiome. Emollient treatment induces change in bacterial microbiome in AD, but its effect on fungal microbiome ("mycobiome") and their inter-kingdom correlations is unknown. We used Ion-Torrent sequencing to characterize the mycobiome of AD patients in response to emollient treatment. METHODS: Skin swabs were collected from lesional and non-lesional skin of AD patients suffering from moderate AD, after informed consent and according to GCP guidelines...
October 1, 2018: Journal of Drugs in Dermatology: JDD
Jewell V Gaulding, Daniel Gutierrez, Bhavnit K Bhatia, Xiaoxia Han, Richard Krajenta, Christine Neslund-Dudas, Henry W Lim, Ellen N Pritchett
BACKGROUND: Epidemiologic studies of patients who present to dermatology clinics are necessary to identify the needs of patients. OBJECTIVE: To quantify and compare diagnoses according to race, ethnicity, and socioeconomic status (SES) at 6 general dermatology clinics from January 2013 to December 2016. METHODS: A retrospective cohort of new patients was established using an electronic medical record database. Primary diagnoses and diagnostic codes were recorded...
October 1, 2018: Journal of Drugs in Dermatology: JDD
Philip R Cohen
I read with interest the informative article by Spencer et al1 that describes the efficacious use as a novel skin lightening agent (LumaPro-C) for the treatment of patients with melasma.
September 1, 2018: Journal of Drugs in Dermatology: JDD
Neil Sadick
When rejuvenating the face with soft tissue fillers, one must consider its structural framework, and patient specific goals/needs holistically to achieve natural results.
September 1, 2018: Journal of Drugs in Dermatology: JDD
Tudor Puiu, Tasneem F Mohammad, David M Ozog, Pranita V Rambhatla
Microneedling was first described in 1995 by Orentreich and Orentreich for the treatment of atrophic scars and wrinkles.<sup>1</sup> The local injury induced by dermal penetration of microneedling causes release of growth factors such as transforming growth factor (TGF)-α, TGF-β, and platelet-derived growth factor (PDGF). This stimulates collagen and elastin fiber production as well as capillary formation, ultimately leading to tissue remodeling.<sup>2</sup>.
September 1, 2018: Journal of Drugs in Dermatology: JDD
Antonella Melina, Nhan Ngo Dinh, Benedetta Tafuri, Giusy Schipani, Steven Nisticò, Carlo Cosentino, Francesco Amato, Diane Thiboutot, Andrea Cherubini
INTRODUCTION: The evaluation of Acne using ordinal scales reflects the clinical perception of severity but has shown low reproducibility both intra- and inter-rater. In this study, we investigated if Artificial Intelligence trained on images of Acne patients could perform acne grading with high accuracy and reliabilities superior to those of expert physicians. METHODS: 479 patients with acne grading ranging from clear to severe and sampled from three ethnic groups participated in this study...
September 1, 2018: Journal of Drugs in Dermatology: JDD
Monica Boen, Marwan Alhaddad, Isabella Guiha, Douglas P Wu, Mitchel P Goldman
INTRODUCTION: Lip plumpers are topical agents that offer immediate, but temporary, volumization of the lips. While these products are becoming increasingly popular and are available at multiple retailers, there is a lack of clinical studies to evaluate the efficacy, longevity, and safety of the lip plumping products. METHODS: This is a prospective, single center, clinical trial to evaluate the duration, efficacy, and safety of a lip plumping agent in two clinical visits...
September 1, 2018: Journal of Drugs in Dermatology: JDD
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"